¿Affymetrix Inc., of Santa Clara Calif., saw its stock (NASDAQ:AFFX) jump more than 12 percent Monday to close at $125 on the strength of its response to a lawsuit brought by Incyte Genomics Inc., of Palo Alto, Calif., alleging patent infringement. Affymetrix said the patents in question claim a specific sample preparation technique and were issued only in the U.S., and that it has a strong defense based on prior art, some of which was developed at Affymetrix.
¿Alliance Pharmaceutical Corp., of San Diego, said the FDA has informed it of the "approvable" status of its new drug application for Imagent, an ultrasound contrast agent. The compound is in development jointly with Schering AG, of Frankfurt, Germany.
¿Antex Biologics Inc., of Gaithersburg, Md., said its stock will trade on the American Stock Exchange, effective immediately, under the symbol "ANX." The company develops vaccines and antibiotics against infections and related diseases.
¿Aronex Pharmaceuticals Inc., of The Woodlands, Texas, said the FDA accepted for review an amendment to Aronex's new drug application for Atragen, the company's treatment for patients with acute promyelocytic leukemia (APL) who require tretinoin therapy and intravenus administration. Aronex plans to evaluate the compound's potential for treatment of non-Hodgkin's lymphoma, hormone-resistant prostrate cancer, acute myelogenous leukemia and renal cell carcinoma in combination with interferon-alpha in addition to investigating the safety and efficacy of the drug for APL.
¿BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., said it entered an option license agreement with Antex Biologics Inc., of Gaithersburg, Md., for the development of BioSante's calcium phosphate nanoparticle (CAP) platform as a vaccine adjuvant. BioSante will formulate vaccines using its CAP platform and Antex's proprietary Chlamydia and H. pylori antigens for testing by Antex in animal models.
¿Cel-Sci Corp., of Vienna, Va., said health authorities for the Czech Republic granted permission for the company to begin Phase II clinical trials in head and neck cancer patients of Multikine, a natural mixture of human immune system regulators. Multikine will be administered as a pre-surgery treatment for 18 days.
¿ChromaVision Medical Systems Inc., of San Juan Capistrano, Calif., completed a fully blinded study that demonstrated an improvement in pathologist accuracy when the company's Automated Cellular Imaging System (ACIS) was used to assist in qualifying a patient for Herceptin therapy. The study showed that the pathologist with the lowest manual accuracy improved to the highest level of manual accuracy when using ACIS.
¿Genomics Collaborative Inc., of Cambridge, Mass., appointed Michael Pellini chief executive officer. Pellini is the former chief operating officer.
¿Ilex Oncology Inc., of San Antonio, Texas, said it responded to the FDA's complete response letter sent in June, regarding a December 1999 biologics license application for Campath (alemtuzumab), an investigational humanized monoclonal antibody. It was submitted in collaboration with joint venture partner Millennium Pharmaceuticals Inc., of Cambridge, Mass. Further information concerning the BLA was not disclosed.
¿Immune Network Ltd., of Vancouver, British Columbia, said it has completed its acquisition of about two-thirds controlling interest in technology innovator BC Research Inc., also of British Columbia. Immune network issued 7.53 million shares and an equal amount of Class A convertible preferred shares as payment for the company.
¿MedImmune Inc., of Gaithersburg, Md., said David Mott's transition into the chief executive officer position will be effective Oct. 1. Mott will replace Wayne Hockmeyer, who will remain chairman.
¿Paradigm Genetics Inc., of Research Triangle Park, N.C., said it will receive an undisclosed milestone payment from Pharmacia Corp., after it surpassed the agreed-upon milestone by delivering 20 percent more gene function data than required by the companies' agreement. The collaboration calls for Paradigm to use its GeneFunction Factory to determine the function of Pharmacia provided genes for use in nutrition and crop production products.
¿Stressgen Biotechnologies Corp., of Victoria, British Columbia, said data indicating its lead product, HspE7, a recombinant fusion protein, invokes a cytotoxic T-cell response was published in Clinical and Experimental Immunology. According to the data, HspE7 is also CD4+ independent. HspE7 is composed of heat shock protein 65 from Mycobacterium-bovis BCG and the protein E7.